top of page
The Professional Network for Healthcare Experts
Alteogen signs $365 million Hybrozyme licensing deal for subcutaneous biologic
The agreement gives an undisclosed global pharmaceutical company worldwide rights to use Alteogen’s ALT-B4 technology to develop and commercialise a subcutaneous formulation of an existing biologic.
nuaxia
Aug 72 min read
Sanofi’s Sarclisa Escena Receives FDA Approval as First Oncology Drug Delivered Through On-Body Injector
The FDA has approved Sarclisa Escena, a subcutaneous on-body injector formulation of Sanofi’s multiple myeloma therapy isatuximab, becoming the first cancer treatment authorised in the US for delivery through an on-body injector system. Sanofi has secured US Food and Drug Administration (FDA) approval for Sarclisa Escena, a new subcutaneous (SC) formulation of its multiple myeloma therapy Sarclisa (isatuximab-irfc) delivered through an on-body injector (OBI). The approval rep
nuaxia
Jul 133 min read
bottom of page